Spruce Biosciences (NASDAQ:SPRB) vs. Evotec (OTCMKTS:EVTCY) Financial Review

Spruce Biosciences (NASDAQ:SPRBGet Free Report) and Evotec (OTCMKTS:EVTCYGet Free Report) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations and valuation.

Insider and Institutional Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. 9.1% of Spruce Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Spruce Biosciences and Evotec’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spruce Biosciences $10.13 million 2.73 -$47.92 million ($1.13) -0.59
Evotec $572.16 million 2.63 $7.14 million $0.41 11.12

Evotec has higher revenue and earnings than Spruce Biosciences. Spruce Biosciences is trading at a lower price-to-earnings ratio than Evotec, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Spruce Biosciences has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500. Comparatively, Evotec has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.


This table compares Spruce Biosciences and Evotec’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Spruce Biosciences -461.67% -57.53% -43.45%
Evotec 20.85% 16.02% 7.81%

Analyst Ratings

This is a summary of recent ratings for Spruce Biosciences and Evotec, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Spruce Biosciences 0 6 2 0 2.25
Evotec 0 0 0 0 N/A

Spruce Biosciences presently has a consensus price target of $5.00, indicating a potential upside of 643.94%. Given Spruce Biosciences’ higher possible upside, equities analysts clearly believe Spruce Biosciences is more favorable than Evotec.


Evotec beats Spruce Biosciences on 7 of the 13 factors compared between the two stocks.

About Spruce Biosciences

(Get Free Report)

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

About Evotec

(Get Free Report)

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Receive News & Ratings for Spruce Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spruce Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.